Hopkins cardiologists and engineers collaborate on new treatments for heart disease

The Alliance for Cardiovascular Diagnostic and Treatment Innovation will oversee clinical trials of biomedical interventions developed at Johns Hopkins

Name
Vanessa Wasta
Email
wasta@jhmi.edu
Office phone
410-955-8236
Name
Rachel Butch
Email
rbutch1@jhmi.edu
Office phone
410-955-8665

In a new $5.5 million center that spans engineering and cardiology specialties at Johns Hopkins, experts aim to improve the diagnosis and treatment of heart rhythm disorders that affect millions of people by leveraging innovations in cardiac imaging, computer simulations, and data science.

The new center, called the Alliance for Cardiovascular Diagnostic and Treatment Innovation, or ADVANCE, is co-led by biomedical engineer Natalia Trayanova, and cardiologist Hugh Calkins.

Trayanova pioneered the use of 3-D virtual replicas of the heart and its electrical function that are personalized to individual patients with certain heart conditions. The simulations help physicians, for example, use radiofrequency waves more precisely to destroy regions in heart tissue believed to sustain and propagate erratic electrical waves.

Trayanova's laboratory also is studying ways to more precisely predict who is at risk for sudden death or stroke from ventricular or atrial fibrillation, two types of irregular heartbeats.

"Our goal is to find new strategies that will have a profound impact on the management of a wide range of cardiac arrhythmias."
Hugh Calkins
Co-leader, Alliance for Cardiovascular Diagnostic and Treatment Innovation

"Establishing this alliance will lead to an exciting blend of engineering and medicine," says Trayanova, a professor in the Department of Biomedical Engineering, which is shared by the Johns Hopkins University Schools of Engineering and Medicine. "It's the culmination of more than five years of collaborations between engineers and clinicians to determine how to solve modern medical problems with computational and data-driven approaches."

Some 5 million people in the U.S. experience atrial fibrillation and tens of thousands more have had ventricular arrhythmias, says Calkins, professor of medicine at the School of Medicine and director of the Cardiac Arrhythmia Service at the Johns Hopkins Hospital.

"Our goal is to find new strategies that will have a profound impact on the management of a wide range of cardiac arrhythmias," says Calkins.

Over the next five years, Calkins and other cardiologists at the Johns Hopkins Hospital will lead clinical trials of the engineering strategies developed by Trayanova and her colleagues.

"ADVANCE is a wonderful example of what can happen when you bring together precisely the right engineers and clinicians with the best and boldest ideas in a collaborative environment," says Ed Schlesinger, dean and professor of electrical and computer engineering at the Whiting School.